科前生物
(688526)
| 流通市值：84.70亿 | | | 总市值：84.70亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 204,929,240.4 | 1,064,074,588.89 | 827,439,173.94 | 531,839,356.71 |
| 营业收入 | 204,929,240.4 | 1,064,074,588.89 | 827,439,173.94 | 531,839,356.71 |
| 二、营业总成本 | 117,548,562.59 | 547,826,665.17 | 407,570,296.65 | 263,731,462.07 |
| 营业成本 | 68,367,813.67 | 296,946,582.34 | 216,956,552.86 | 140,513,632.21 |
| 税金及附加 | 1,316,779.35 | 6,840,333.87 | 4,892,552.6 | 3,249,717 |
| 销售费用 | 31,848,987.78 | 154,836,459.09 | 120,879,001.48 | 73,306,382.26 |
| 管理费用 | 11,186,340.52 | 67,044,235.14 | 48,834,432.15 | 33,824,351.84 |
| 研发费用 | 19,840,800.13 | 88,505,343.58 | 64,500,664.25 | 43,810,307.48 |
| 财务费用 | -15,012,158.86 | -66,346,288.85 | -48,492,906.69 | -30,972,928.72 |
| 其中:利息费用 | 2,005,025.73 | 8,158,805.33 | 6,631,265.57 | 4,359,560.46 |
| 其中:利息收入 | 17,029,790.46 | 74,587,150.96 | 55,190,996.48 | 35,366,794.72 |
| 加:公允价值变动收益 | 878,049.98 | -10,194,774.37 | -7,258,979.09 | -2,297,111.43 |
| 加:投资收益 | 2,893,431.31 | 19,532,528.49 | 14,374,242.08 | 11,291,575.28 |
| 资产处置收益 | 926,906.06 | - | - | - |
| 资产减值损失(新) | -2,903,421.2 | -15,793,212.07 | -4,877,949.67 | -2,502,486.39 |
| 信用减值损失(新) | -478,018.34 | -80,370,379.52 | -24,743,557.99 | -5,134,353.47 |
| 其他收益 | 11,927,047.88 | 29,709,604.66 | 15,380,810.75 | 7,223,947.54 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 100,624,673.5 | 459,131,690.91 | 412,743,443.37 | 276,689,466.17 |
| 加:营业外收入 | 3,434.02 | 134,324.35 | 35,320.7 | 34,820.37 |
| 减:营业外支出 | 618,536.98 | 1,685,350.76 | 1,124,286.62 | 1,718,696.68 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 100,009,570.54 | 457,580,664.5 | 411,654,477.45 | 275,005,589.86 |
| 减:所得税费用 | 12,933,889.88 | 62,000,111.8 | 54,474,391.97 | 36,028,872.36 |
| 六、净利润 | 87,075,680.66 | 395,580,552.7 | 357,180,085.48 | 238,976,717.5 |
| 持续经营净利润 | 87,075,680.66 | 395,580,552.7 | 357,180,085.48 | 238,976,717.5 |
| 归属于母公司股东的净利润 | 87,228,395.78 | 395,934,947.68 | 357,428,181.1 | 239,165,895.22 |
| 少数股东损益 | -152,715.12 | -354,394.98 | -248,095.62 | -189,177.72 |
| (一)基本每股收益 | 0.18 | 0.85 | 0.77 | 0.51 |
| (二)稀释每股收益 | 0.18 | 0.85 | 0.77 | 0.51 |
| 八、其他综合收益 | 3,322,297.47 | 25,333,622.92 | - | - |
| 归属于母公司股东的其他综合收益 | 3,322,297.47 | 25,333,622.92 | - | - |
| 九、综合收益总额 | 90,397,978.13 | 420,914,175.62 | 357,180,085.48 | 238,976,717.5 |
| 归属于母公司股东的综合收益总额 | 90,550,693.25 | 421,268,570.6 | 357,428,181.1 | 239,165,895.22 |
| 归属于少数股东的综合收益总额 | -152,715.12 | -354,394.98 | -248,095.62 | -189,177.72 |
| 公告日期 | 2024-04-30 | 2024-04-02 | 2023-10-27 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |